Clinical proof Cellanyx has demonstrated clinical proof of concept for prostate cancer and Stage 0 breast cancer phenotypic biomarker tests, indicating potential collaboration opportunities with academic medical centers and pathology labs to validate and scale test adoption.

Early-stage focus With a small team and <$1M revenue, Cellanyx is positioned for strategic partnerships to accelerate development and commercialization, particularly by licensing or co-developing tests with larger diagnostic players or contract research organizations.

Prostate risk The flagship prostate cancer phenotypic biomarker test targets enhanced risk stratification at radical prostatectomy, presenting a clear entry point for hospitals and urology practices seeking to augment pathology workflows and decision-making.

Fabrication & tech Cellanyx combines rapid primary tumor cell culture, microfluidics, advanced imaging, and AI analytics, suggesting sales opportunities around laboratory automation, instrumentation partnerships, and data integration with existing pathology IT systems.

Strategic leadership Board addition of industry expertise and proximity to a growing field of liquid/biopsy alternatives presents a path to engage corporate development teams at mid-to-large diagnostics companies for potential collaborations or minority investments.